2023-12-20 19:01:00
Good news may be coming for anxious. After all, the Canadian company MindMed announced that its studies on a remedy of single dose once morest anxiety have reached a new phase. The next step is to hold an end-of-phase meeting with the FDA, which should happen in early 2024.
With this, it can be said that the medicine is a little closer to becoming a reality in the future. For those who don’t know, this drug will act on serotonin receptors and, according to what the company said in its latest study, the primary objective was achieved, which paves the way for the drug to be approved for therapeutic use.
Also according to MindMed, the study included 200 participants who had symptoms of anxiety. Daniel Karlin is the company’s medical director and commented on the so-called MM-120:
Few new treatment options have demonstrated robust activity in generalized anxiety disorder since the last new drug approval in 2004, making the strong, rapid, and durable clinical activity of a single dose of MM-120 observed in the trial particularly notable.
The Canadian company even issued a statement regarding test participants, which states that 78% of them experienced significant relief in symptoms related to the condition compared to placebo. This result was obtained following tests carried out over four weeks.
Anxiety treatment may not be the only application of the drug, which is also the focus of another study testing its possible effectiveness in treating ADHD. It is worth remembering that a company called PureTech is also developing its solution to treat anxiety and its medicine, allopregnanolone (LYT-300), is already in phase 2 of clinical trials.
1703123046
#Singledose #antianxiety #medication #reaches #phase #reality
